Sponsor Check › Person
Related person on Form D filings · address states as listed: NY, A8, CA, NJ, CO, MA, IL · listed Dec 30, 2009 → Dec 10, 2021
Data last updated: Oct 23, 2026, 5:45 PM ET · Courts (RECAP) last checked: Oct 23, 2026, 11:56 PM ET · SEC enforcement last checked: not yet
Privacy: business-related public information only. Residential addresses are never shown; only the state from the filing.
The five facts investors ask about first. Each section states what was searched and when. Items still in human review are not shown.
None found in sources searched.
Sources searched: CourtListener bulk data (RECAP dockets as of 2026-09-30) — federal district + bankruptcy courts; live RECAP re-check pending. State courts: not yet searched. PACER: not searched. · Last checked Oct 23, 2026, 11:56 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
SEC enforcement searched: SEC litigation releases and administrative proceedings — respondent names in the sec.gov index titles (30,205 releases, 1995-09-19 to 2026-10-23); release text is read only to confirm a candidate. Names that appear only in the body of a release are not found. — not yet searched; State securities regulators searched: AZ (Corporation Commission Securities Division), CA (DFPI — 16 of 12,159 DFPI respondent pages read so far; sponsor-name matches are read first), DE (DOJ Investor Protection Unit), TX (State Securities Board), WA (DFI) — last crawled Oct 23, 2026, 9:57 PM ET. Other states: not yet searched.
Not yet searched.
Search queued. Results are added automatically; check back later or follow this page to be notified.
None found in sources searched.
Sources searched: Federal bankruptcy courts via CourtListener / RECAP archive (federal district courts, federal bankruptcy courts). State courts: not yet searched. PACER: not searched (RECAP only). · Last checked Oct 23, 2026, 11:56 PM ET.
State courts: not yet searched. No state offers a lawful automated statewide source PartnerFacts can use today. Texas (re:SearchTX) terms prohibit storing results in a database open to third parties; New York (WebCivil) and Massachusetts (MassCourts) require a browser check that blocks scripted queries; California has no statewide index (58 county portals; Rule of Court 2.503 grants name-based access case by case); Florida, Utah and Illinois offer paid or partial access whose terms for automated use are unverified. Washington (dw.courts.wa.gov; bulk index reports under a JISC data-dissemination agreement), Delaware (CourtConnect; Court of Chancery not included) and Arizona (apps.azcourts.gov/publicaccess, which has an official channel to request high-volume access) are the candidates; PartnerFacts will request written permission before any automated search. Federal courts are searched through CourtListener / RECAP.
Comparisons are made for sponsors and sponsor groups, not individual people.
10 of 55 offerings report sales commissions totalling $46,505,682; 0 report finder's fees; 0 report proceeds to related persons. (includes amounts the issuer reported as estimates)
| Source | Offering (latest filing) | Sales commissions | Finder's fees | To insiders | Paid to sell it |
|---|---|---|---|---|---|
| EDGAR ↗ | Jul 5, 2024 D File 021-517876 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 10, 2021 D/A File 021-355430 | $0 | $0 | $0 The fund charges a management fee that is described in the fund's offering documents. | None listed on this filing |
| EDGAR ↗ | Sep 15, 2021 D File 021-413372 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 16, 2021 D/A File 021-128771 | $30,728,808 (est.) | $0 | $0 The fund charges a management fee that is described in the fund's offering documents. | Far Hills Group, LLC BrokerCheck CRD 32243 ↗ J.P. Morgan Securities LLC BrokerCheck CRD 79 ↗ |
| EDGAR ↗ | Jul 16, 2021 D/A File 021-212193 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 16, 2021 D/A File 021-220964 | $0 | $0 | $0 The fund charges a management fee that is described in the fund's offering documents. | None listed on this filing |
| EDGAR ↗ | Apr 14, 2021 D/A File 021-364898 | $0 | $0 | $0 The fund charges a management fee that is described in the fund's offering documents. | None listed on this filing |
| EDGAR ↗ | Sep 2, 2020 D/A File 021-362067 | $0 (est.) | $0 (est.) | $0 (est.) An affiliate of the GPLP and GPLTD will receive a fee for management services. The fee will equal a percentage of aggregate subscriptions of the Issuer's limited partners during the investment period and a percentage of invested capital thereafter. | J.P. Morgan Securities LLC BrokerCheck CRD 79 ↗ |
| EDGAR ↗ | Aug 27, 2020 D File 021-374300 | $0 | $0 | $0 An affiliate of the General Partner will receive a fee for management services equal to a percentage of aggregate subscriptions of the Issuer's limited partners during the investment period and a percentage of invested capital thereafter. | None listed on this filing |
| EDGAR ↗ | Oct 22, 2019 D File 021-351627 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 7, 2019 D File 021-350518 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 3, 2019 D/A File 021-331673 | $0 (est.) | $0 (est.) | $0 (est.) An affiliate of the General Partner will receive a fee for management services. The fee will equal a percentage of aggregate subscriptions of the Issuer's limited partners during the investment period and a percentage of invested capital thereafter. | J.P. Morgan Securities LLC BrokerCheck CRD 79 ↗ |
| EDGAR ↗ | Oct 26, 2018 D/A File 021-246441 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | May 11, 2018 D File 021-312182 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 30, 2018 D File 021-304413 | $0 | $0 | $0 (est.) An affiliate of the General Partner will receive a fee for management services. The fee will equal a percentage of aggregate subscriptions of the Issuer's limited partners during the investment period and a percentage of invested capital thereafter. | None listed on this filing |
| EDGAR ↗ | Sep 6, 2017 D/A File 021-281414 | $2,478,300 | $0 | $0 (est.) An affiliate of the GPLP will receive a fee for management services. The fee will equal a percentage of aggregate subscriptions of the Issuer's limited partners during the investment period and a percentage based on invested capital thereafter. | J.P. Morgan Securities LLC BrokerCheck CRD 79 ↗ |
| EDGAR ↗ | Aug 8, 2017 D/A File 021-277965 | $0 | $0 | $0 (est.) Proceeds will be used for general corporate purposes including, but not limited to, executive salaries | None listed on this filing |
| EDGAR ↗ | Jul 14, 2017 D/A File 021-91544-4N | $3,228,724 (est.) | $0 | $0 The fund charges a management fee that is described in the fund's offering documents. | Far Hills Group, LLC BrokerCheck CRD 32243 ↗ |
| EDGAR ↗ | May 1, 2017 D File 021-285796 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 20, 2017 D File 021-278910 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jan 6, 2017 D File 021-277857 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 30, 2016 D File 021-271657 | $949,850 | $0 | $0 (est.) The proceeds are expected to be used for general corporate purposes which may include the payment of salaries and other fees to those listed in Item 3. | Roth Capital Partners, LLC BrokerCheck CRD 15407 ↗ |
| EDGAR ↗ | Sep 26, 2016 D File 021-271250 | $500,000 | $0 | $0 | Leerink Partners LLC BrokerCheck CRD 39011 ↗ |
| EDGAR ↗ | Jan 27, 2016 D File 021-256078 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 14, 2015 D File 021-253036 | $0 | $0 | $0 (est.) An affiliate of the GPLP will receive a fee for management services. The fee will equal a percentage of aggregate subscriptions of the Issuer's limited partners during the investment period and a percentage of invested capital thereafter. | None listed on this filing |
| EDGAR ↗ | Dec 10, 2015 D/A File 021-245580 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 22, 2015 D File 021-249874 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 15, 2015 D File 021-247616 | $0 | $0 | $0 (est.) An affiliate of the General Partner will receive a fee for management services. The fee will equal a percentage of aggregate subscriptions of the Issuer's limited partners during the investment period and a percentage of invested capital thereafter. | None listed on this filing |
| EDGAR ↗ | Sep 2, 2015 D File 021-246838 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 23, 2015 D File 021-234532 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 2, 2015 D File 021-233267 | $1,500,000 | $0 | $0 (est.) An affiliate of the General Partner will receive a fee for management services. The fee will equal a percentage of aggregate subscriptions of the Issuer's limited partners during the investment period and a percentage of invested capital thereafter. | Merrill Lynch, Pierce, Fenner & Smith Incorporated BrokerCheck CRD 7691 ↗ |
| EDGAR ↗ | Dec 24, 2014 D File 021-230835 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 31, 2013 D File 021-209047 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 5, 2013 D File 021-207477 | $0 | $0 | $0 (est.) A portion of the proceeds may be used for general corporate purposes. Salaries and/or director fees may be paid to certain related persons in Item 3. The amount of such fees cannot be determined as this time. | None listed on this filing |
| EDGAR ↗ | Nov 5, 2013 D File 021-205773 | $1,740,000 (est.) | $0 | $0 (est.) An affiliate of the General Partner will receive a fee for management services. The fee will equal a percentage of aggregate subscriptions of the Issuer's limited partners during the investment period and a percentage of invested capital thereafter. | Merrill Lynch, Pierce, Fenner & Smith Incorporated BrokerCheck CRD 7691 ↗ |
| EDGAR ↗ | Aug 15, 2013 D File 021-201444 | $0 (est.) | $0 | $0 (est.) An affiliate of the General Partner will receive a fee for management services. The fee will equal a percentage of aggregate subscriptions of the Issuer's limited partners during the investment period and a percentage of invested capital thereafter. | Merrill Lynch, Pierce, Fenner & Smith Incorporated BrokerCheck CRD 7691 ↗ |
| EDGAR ↗ | Jun 27, 2013 D File 021-198730 | $0 (est.) | $0 (est.) | $0 (est.) A portion of the proceeds may be used for general corporate purposes. Salaries and/or director fees may be paid to certain related persons in Item 3. The amount of such fees cannot be determined as this time. | None listed on this filing |
| EDGAR ↗ | Jan 25, 2013 D File 021-190823 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 11, 2012 D/A File 021-182532 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Nov 27, 2012 D/A File 021-181546 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 3, 2012 D File 021-184931 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Sep 4, 2012 D/A File 021-183201 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 10, 2012 D File 021-182573 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Feb 16, 2012 D File 021-173576 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Oct 5, 2011 D File 021-166773 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Aug 24, 2011 D File 021-164842 | $1,300,000 (est.) | $0 | $0 The net proceeds of the offering will be used for general corporate and working capital purposes, a portion of which may be applied to pay executive officers and directors. | None listed on this filing |
| EDGAR ↗ | Aug 8, 2011 D/A File 021-147705 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Apr 18, 2011 D File 021-158558 | $1,830,000 (est.) | $0 | $0 (est.) An affiliate of the General Partner will receive an annual fee for management services. Amount to be paid, number of years to be paid and extent paid out of adjusted gross proceeds are unknown at this time | J.P. Morgan Securities LLC BrokerCheck CRD 79 ↗ |
| EDGAR ↗ | Apr 1, 2011 D File 021-157715 | $0 | $0 | $0 Proceeds are applied to general corporate and working capital purposes, a portion of which may be applied to pay executive officers and directors. | None listed on this filing |
| EDGAR ↗ | Feb 1, 2011 D File 021-154689 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 13, 2010 D/A File 021-109028 | $0 | $0 | $0 Proceeds are applied to general corporate and working capital purposes, a portion of which may be applied to pay executive officers and directors. | None listed on this filing |
| EDGAR ↗ | Sep 23, 2010 D File 021-148086 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Jul 15, 2010 D File 021-145053 | $0 | $0 | $0 | None listed on this filing |
| EDGAR ↗ | Dec 30, 2009 D File 021-137285 | $2,250,000 (est.) | $0 | $0 (est.) An affiliate of the General Partner will receive a fee for management services. The fee will equal a percentage of the aggregate subscriptions of the Issuer's limited partners during the investment period, and a percentage of invested capital thereafter. | J.P. Morgan Securities Inc. BrokerCheck CRD 79 ↗ |
| EDGAR ↗ | Mar 30, 2009 D File 021-101063 | $0 | $0 | $0 | None listed on this filing |
As reported by the issuer on Form D (Items 12–15), latest filing per offering (one offering = one SEC file number; an amendment updates its offering rather than adding one). "To insiders" = gross proceeds used for payments to executive officers, directors or promoters. "—" = not reported on that filing. Amounts marked (est.) were reported as estimates. "Paid to sell it" = sales compensation recipients named on that filing (Item 12), each linked to FINRA BrokerCheck when a CRD number is reported.
Counted across every filing this person is listed on (latest filing per offering, per issuer).
| Source | Issuer | Role | Filed | Form | Offering | Sold | Investors | Min. investment |
|---|---|---|---|---|---|---|---|---|
| EDGAR ↗ | VANQUA BIO, INC. group: Orbimed | Director | Jul 5, 2024 | D | $44,979,987 similar: $2,000,000–$19,999,994 | $44,979,987 | 12 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | OrbiMed Genesis Fund, L.P. group: Orbimed | Executive Officer Member of the Managing Member of the General Partner | Dec 10, 2021 | D/A | Indefinite similar: $155,000–$5,250,000 | $184,125,000 | 64 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | VANQUA BIO, INC. group: Orbimed | Director | Sep 15, 2021 | D | $84,999,987 similar: $2,000,000–$19,999,994 | $84,999,987 | 11 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | OrbiMed Partners II, L.P. group: Orbimed | Executive Officer Member of OrbiMed Advisors | Jul 16, 2021 | D/A | Indefinite similar: $155,000–$5,250,000 | $1,770,099,650 | 874 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Global Healthcare Fund, L.P. group: Orbimed | Executive Officer Member of the Managing Member of the General Partner | Jul 16, 2021 | D/A | Indefinite similar: $155,000–$5,250,000 | $113,350,000 | 10 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Global Healthcare Associates Fund, L.P. group: Orbimed | Executive Officer Member of the Managing Member of the General Partner | Jul 16, 2021 | D/A | Indefinite similar: $155,000–$5,250,000 | $17,150,000 | 7 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed New Horizons Fund, L.P. group: Orbimed | Executive Officer Member of the Managing Member of the General Partner | Apr 14, 2021 | D/A | Indefinite similar: $155,000–$5,250,000 | $47,325,000 | 47 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Genesis Fund, L.P. group: Orbimed | Executive Officer Member of the Managing Member of the General Partner | Dec 11, 2020 | D/A | Indefinite similar: $155,000–$5,250,000 | $59,275,000 | 24 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Asia Partners IV, L.P. group: Orbimed | Director Director of the GPLTD | Sep 2, 2020 | D/A | $750,000,000 similar: $155,000–$5,250,000 | $486,882,011 | 86 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Private Investments VIII, LP group: Orbimed | Executive Officer Member of OrbiMed Advisors | Aug 27, 2020 | D | $1,400,000,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Global Healthcare Fund, L.P. group: Orbimed | Executive Officer Member of the Managing Member of the General Partner | Jul 16, 2020 | D/A | Indefinite similar: $155,000–$5,250,000 | $113,350,000 | 10 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Global Healthcare Associates Fund, L.P. group: Orbimed | Executive Officer Member of the Managing Member of the General Partner | Jul 16, 2020 | D/A | Indefinite similar: $155,000–$5,250,000 | $17,150,000 | 7 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Partners II, L.P. group: Orbimed | Executive Officer Member of OrbiMed Advisors | Jul 16, 2020 | D/A | Indefinite similar: $155,000–$5,250,000 | $1,749,614,118 | 849 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed New Horizons Fund, L.P. group: Orbimed | Executive Officer Member of the Managing Member of the General Partner | Apr 14, 2020 | D | Indefinite similar: $155,000–$5,250,000 | $25,300,000 | 10 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Asia Partners IV, L.P. group: Orbimed | Director Director of the GPLTD | Mar 5, 2020 | D | $750,000,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Genesis Fund, L.P. group: Orbimed | Executive Officer Member of the Managing Member of the General Partner | Dec 12, 2019 | D | Indefinite similar: $155,000–$5,250,000 | $50,100,000 | 15 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Arcutis Biotherapeutics, Inc. | Director | Oct 22, 2019 | D | $94,500,000 similar: $2,000,000–$19,999,994 | $94,499,967 | 16 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | VANQUA BIO, INC. group: Orbimed | Executive Officer, Director President & Director | Oct 7, 2019 | D | $18,000,000 similar: $1,100,015–$10,001,163 | $6,000,000 | 1 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | OrbiMed Global Healthcare Associates Fund, L.P. group: Orbimed | Executive Officer Member of the Managing Member of the General Partner | Jul 16, 2019 | D/A | Indefinite similar: $155,000–$5,250,000 | $17,150,000 | 7 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Global Healthcare Fund, L.P. group: Orbimed | Executive Officer Member of the Managing Member of the General Partner | Jul 16, 2019 | D/A | Indefinite similar: $155,000–$5,250,000 | $113,350,000 | 10 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Partners II, L.P. group: Orbimed | Executive Officer Member of OrbiMed Advisors | Jul 16, 2019 | D/A | Indefinite similar: $155,000–$5,250,000 | $1,738,864,013 | 842 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Royalty & Credit Opportunities III, LP group: Orbimed | Executive Officer Member of OrbiMed Advisors | Jul 3, 2019 | D/A | $1,200,000,000 similar: $155,000–$5,250,000 | $889,835,000 | 69 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Royalty & Credit Opportunities III, LP group: Orbimed | Executive Officer Member of OrbiMed Advisors | Jan 29, 2019 | D | $1,200,000,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Adicet Bio, Inc. | Director | Oct 26, 2018 | D/A | $43,318,510 similar: $2,000,000–$19,999,994 | $25,443,510 | 5 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | OrbiMed Partners II, L.P. group: Orbimed | Executive Officer Member of OrbiMed Advisors | Jul 16, 2018 | D/A | Indefinite similar: $155,000–$5,250,000 | $1,714,214,013 | 835 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Global Healthcare Fund, L.P. group: Orbimed | Executive Officer Member of the Managing Member of the General Partner | Jul 16, 2018 | D/A | Indefinite similar: $155,000–$5,250,000 | $113,350,000 | 10 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Global Healthcare Associates Fund, L.P. group: Orbimed | Executive Officer Member of the Managing Member of the General Partner | Jul 16, 2018 | D/A | Indefinite similar: $155,000–$5,250,000 | $17,150,000 | 7 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | AVEDRO INC | Director | May 11, 2018 | D | $24,999,971 similar: $829,831–$9,999,998 | $24,999,971 | 19 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | OrbiMed Private Investments VII, LP group: Orbimed | Executive Officer Member of OrbiMed Advisors | Jan 30, 2018 | D | $1,000,000,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Asia Partners III, L.P. group: Orbimed | Director Director of the GPLTD | Sep 6, 2017 | D/A | $539,960,000 similar: $155,000–$5,250,000 | $539,960,000 | 97 similar: 4–27 | $100,000 similar: $1,000–$100,000 |
| EDGAR ↗ | NeuroPace Inc | Director | Aug 8, 2017 | D/A | $80,000,001 similar: $829,831–$9,999,998 | $72,000,001 | 26 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | OrbiMed Partners, L.P. group: Orbimed | Executive Officer Member of OrbiMed Advisors | Jul 14, 2017 | D/A | Indefinite similar: $155,000–$5,250,000 | $128,115,033 | 130 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Partners II, L.P. group: Orbimed | Executive Officer Member of OrbiMed Advisors | Jul 14, 2017 | D/A | Indefinite similar: $155,000–$5,250,000 | $1,643,696,853 | 797 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Global Healthcare Fund, L.P. group: Orbimed | Executive Officer Member of the Managing Member of the General Partner | Jul 14, 2017 | D/A | Indefinite similar: $155,000–$5,250,000 | $113,350,000 | 10 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Global Healthcare Associates Fund, L.P. group: Orbimed | Executive Officer Member of the Managing Member of the General Partner | Jul 14, 2017 | D/A | Indefinite similar: $155,000–$5,250,000 | $17,150,000 | 7 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Asia Partners III, L.P. group: Orbimed | Director Director of the GPLTD | Jun 28, 2017 | D/A | $450,000,000 similar: $155,000–$5,250,000 | $431,530,000 | 95 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | AVEDRO INC | Director | May 1, 2017 | D | $12,000,003 similar: $829,831–$9,999,998 | $12,000,003 | 14 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | OrbiMed Asia Partners III, L.P. group: Orbimed | Director Director of the GPLTD | Mar 1, 2017 | D/A | $450,000,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Asia Partners III, L.P. group: Orbimed | Director Director of the GPLTD | Feb 27, 2017 | D | $450,000,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | RHYTHM PHARMACEUTICALS, INC. group: Rhythm Pharmaceuticals | Director | Jan 20, 2017 | D | $40,949,999 similar: $1,694,259–$16,000,000 | $20,475,001 | 14 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | scPharmaceuticals Inc. | Director | Jan 6, 2017 | D | $46,962,788 similar: $1,694,259–$16,000,000 | $46,962,788 | 11 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Roka BioScience, Inc. | Director | Sep 30, 2016 | D | $22,500,000 similar: $2,000,000–$19,999,994 | $22,500,000 | 32 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | CERAPEDICS INC | Director | Sep 26, 2016 | D | $14,000,000 similar: $2,000,000–$19,999,994 | $11,000,000 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | OrbiMed Global Healthcare Associates Fund, L.P. group: Orbimed | Executive Officer Member of the Managing Member of the General Partner | Jul 14, 2016 | D/A | Indefinite similar: $155,000–$5,250,000 | $17,150,000 | 7 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Global Healthcare Fund, L.P. group: Orbimed | Executive Officer Member of the Managing Member of the General Partner | Jul 14, 2016 | D/A | Indefinite similar: $155,000–$5,250,000 | $113,350,000 | 10 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Partners II, L.P. group: Orbimed | Executive Officer Member of OrbiMed Advisors | Jul 14, 2016 | D/A | Indefinite similar: $155,000–$5,250,000 | $1,565,361,853 | 744 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Partners, L.P. group: Orbimed | Executive Officer Member of OrbiMed Advisors | Jul 14, 2016 | D/A | Indefinite similar: $155,000–$5,250,000 | $127,850,033 | 128 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Adicet Bio, Inc. | Director | Jan 27, 2016 | D/A | $43,318,510 similar: $2,000,000–$19,999,994 | $25,443,510 | 5 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Adicet Bio, Inc. | Director | Jan 27, 2016 | D | $13,935,086 similar: $2,000,000–$19,999,994 | $11,313,608 | 6 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | OrbiMed Israel Partners II, L.P. group: Orbimed | Executive Officer | Dec 14, 2015 | D | $300,000,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | RHYTHM PHARMACEUTICALS, INC. group: Rhythm Pharmaceuticals | Director | Dec 10, 2015 | D/A | $40,000,000 similar: $1,694,259–$16,000,000 | $40,000,000 | 12 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | Audentes Therapeutics, Inc. | Director | Oct 22, 2015 | D | $64,999,949 similar: $2,000,000–$19,999,994 | $64,999,949 | 27 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | OrbiMed Private Investments VI, LP group: Orbimed | Executive Officer Member of OrbiMed Advisors | Sep 15, 2015 | D | $950,000,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Audentes Therapeutics, Inc. | Director | Sep 2, 2015 | D | Indefinite similar: $2,000,000–$19,999,994 | $0 | 21 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Adicet Bio, Inc. | Director | Aug 26, 2015 | D | $40,000,000 similar: $2,000,000–$19,999,994 | $14,625,000 | 1 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | OrbiMed Partners II, L.P. group: Orbimed | Executive Officer Member of OrbiMed Advisors | Jul 14, 2015 | D/A | Indefinite similar: $155,000–$5,250,000 | $1,346,181,853 | 624 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Partners, L.P. group: Orbimed | Executive Officer Member of OrbiMed Advisors | Jul 14, 2015 | D/A | Indefinite similar: $155,000–$5,250,000 | $124,585,033 | 127 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Global Healthcare Associates Fund, L.P. group: Orbimed | Executive Officer Member of the Managing Member of the General Partner | Jul 14, 2015 | D/A | Indefinite similar: $155,000–$5,250,000 | $17,150,000 | 7 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Global Healthcare Fund, L.P. group: Orbimed | Executive Officer Member of the Managing Member of the General Partner | Jul 14, 2015 | D/A | Indefinite similar: $155,000–$5,250,000 | $11,250,000 | 7 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | CERAPEDICS INC | Director | Feb 23, 2015 | D | $4,000,000 similar: $2,000,000–$19,999,994 | $4,000,000 | 5 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | OrbiMed Global Healthcare Associates Fund, L.P. group: Orbimed | Executive Officer Member of the Managing Member of the General Partner | Feb 11, 2015 | D/A | Indefinite similar: $155,000–$5,250,000 | $17,150,000 | 7 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Royalty Opportunities II, LP group: Orbimed | Executive Officer Member of OrbiMed Advisors | Feb 2, 2015 | D | $900,000,000 similar: $155,000–$5,250,000 | $900,000,000 | 83 similar: 4–27 | $750,000 similar: $1,000–$100,000 |
| EDGAR ↗ | Audentes Therapeutics, Inc. | Director | Dec 24, 2014 | D | $42,500,002 similar: $2,000,000–$19,999,994 | $42,500,002 | 11 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | OrbiMed Partners II, L.P. group: Orbimed | Executive Officer, Promoter Member of OrbiMed Advisors | Jul 14, 2014 | D/A | Indefinite similar: $155,000–$5,250,000 | $1,142,846,853 | 528 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Partners, L.P. group: Orbimed | Executive Officer, Promoter Member of OrbiMed Advisors | Jul 14, 2014 | D/A | Indefinite similar: $155,000–$5,250,000 | $117,935,033 | 121 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Global Healthcare Fund, L.P. group: Orbimed | Executive Officer Member of the Managing Member of the General Partner | Jul 14, 2014 | D | Indefinite similar: $155,000–$5,250,000 | $6,000,000 | 2 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Global Healthcare Associates Fund, L.P. group: Orbimed | Executive Officer Member of the Managing Member of the General Partner | Feb 19, 2014 | D | Indefinite similar: $155,000–$5,250,000 | $600,000 | 2 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | DFINE INC | Director | Dec 31, 2013 | D | $17,490,000 similar: $500,000–$7,000,000 | $17,487,929 | 12 similar: 2–14 | No minimum reported similar: $5,000–$50,000 |
| EDGAR ↗ | Roka BioScience, Inc. | Director | Dec 5, 2013 | D | $16,996,657 similar: $2,000,000–$19,999,994 | $16,996,657 | 5 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | OrbiMed Private Investments V, LP group: Orbimed | Executive Officer Member of OrbiMed Advisors | Nov 5, 2013 | D | $700,000,000 similar: $155,000–$5,250,000 | $699,500,000 | 66 similar: 4–27 | $150,000 similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Asia Partners II, LP group: Orbimed | Director Director of the general partner of the general partner of the Issuer | Aug 15, 2013 | D | $300,000,000 similar: $155,000–$5,250,000 | $0 | 0 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Partners II, L.P. group: Orbimed | Executive Officer, Promoter Member of OrbiMed Advisors | Jul 12, 2013 | D/A | Indefinite similar: $155,000–$5,250,000 | $836,672,000 | 372 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Partners, L.P. group: Orbimed | Executive Officer, Promoter Member of OrbiMed Advisors | Jul 12, 2013 | D/A | Indefinite similar: $155,000–$5,250,000 | $112,641,000 | 119 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Roka BioScience, Inc. | Director | Jun 27, 2013 | D | $24,999,999 similar: $2,000,000–$19,999,994 | $24,999,999 | 5 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | OrbiMed Partners II, L.P. group: Orbimed | Executive Officer, Promoter Member of OrbiMed Advisors | Mar 12, 2013 | D/A | Indefinite similar: $155,000–$5,250,000 | $640,107,000 | 299 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Partners, L.P. group: Orbimed | Executive Officer, Promoter Member of OrbiMed Advisors | Mar 12, 2013 | D/A | Indefinite similar: $155,000–$5,250,000 | $111,731,000 | 118 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | GLAUKOS Corp | Director | Jan 25, 2013 | D | $30,000,002 similar: $829,831–$9,999,998 | $30,000,002 | 20 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Relypsa Inc | Director | Dec 11, 2012 | D/A | $80,000,200 similar: $1,694,259–$16,000,000 | $65,000,192 | 15 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | CERAPEDICS INC | Director | Nov 27, 2012 | D/A | $19,090,328 similar: $2,000,000–$19,999,994 | $0 | 5 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Relypsa Inc | Director | Oct 5, 2012 | D/A | $80,000,200 similar: $1,694,259–$16,000,000 | $62,412,304 | 14 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | GLAUKOS Corp | Director | Oct 3, 2012 | D | $6,000,000 similar: $829,831–$9,999,998 | $6,000,000 | 11 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | INTERCEPT PHARMACEUTICALS INC | Director | Sep 4, 2012 | D/A | $50,000,000 similar: $2,000,000–$19,999,994 | $30,000,000 | 2 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | INTERCEPT PHARMACEUTICALS INC | Director | Aug 24, 2012 | D | $30,000,000 similar: $2,000,000–$19,999,994 | $15,000,000 | 2 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | GLAUKOS Corp | Director | Aug 10, 2012 | D | $4,500,000 similar: $829,831–$9,999,998 | $4,500,000 | 14 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Relypsa Inc | Director | Aug 10, 2012 | D | $80,000,200 similar: $1,694,259–$16,000,000 | $49,677,652 | 13 similar: 1–13 | No minimum reported similar: $10,000–$55,000 |
| EDGAR ↗ | CERAPEDICS INC | Director | Jul 20, 2012 | D | $18,090,328 similar: $2,000,000–$19,999,994 | $12,090,328 | 4 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | OrbiMed Partners II, L.P. group: Orbimed | Executive Officer, Promoter Member of OrbiMed Advisors | Mar 12, 2012 | D/A | Indefinite similar: $155,000–$5,250,000 | $446,081,853 | 209 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Partners, L.P. group: Orbimed | Executive Officer, Promoter Member of OrbiMed Advisors | Mar 12, 2012 | D/A | Indefinite similar: $155,000–$5,250,000 | $110,685,733 | 117 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | CERAPEDICS INC | Director | Feb 16, 2012 | D | $3,000,000 similar: $2,000,000–$19,999,994 | $3,000,000 | 3 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | DFINE INC | Director | Oct 5, 2011 | D | $26,500,000 | $14,981,562 | 16 | $1 |
| EDGAR ↗ | Enobia Pharma Corp | Director | Aug 24, 2011 | D | $40,000,000 similar: $2,000,000–$19,999,994 | $20,000,000 | 3 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | Relypsa Inc | Director | Aug 8, 2011 | D/A | $70,129,747 similar: $2,000,000–$19,999,994 | $70,129,747 | 12 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | OrbiMed Israel Partners Limited Partnership group: Orbimed | Executive Officer | Apr 18, 2011 | D | Indefinite similar: $155,000–$5,250,000 | $190,375,000 | 50 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Enobia Pharma Corp | Director | Apr 1, 2011 | D | $46,969,070 similar: $2,000,000–$19,999,994 | $15,000,000 | 7 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | OrbiMed Partners II, L.P. group: Orbimed | Executive Officer, Promoter Member of OrbiMed Advisors | Mar 11, 2011 | D/A | Indefinite similar: $155,000–$5,250,000 | $236,139,926 | 91 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | OrbiMed Partners, L.P. group: Orbimed | Executive Officer, Promoter Member of OrbiMed Advisors | Mar 11, 2011 | D/A | Indefinite similar: $155,000–$5,250,000 | $64,608,125 | 50 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | GLAUKOS Corp | Director | Feb 1, 2011 | D | $29,500,003 similar: $829,831–$9,999,998 | $29,500,003 | 18 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Enobia Pharma Corp | Director | Dec 13, 2010 | D/A | $50,000,000 similar: $2,000,000–$19,999,994 | $50,000,000 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | GLAUKOS Corp | Director | Sep 23, 2010 | D | $6,000,392 similar: $829,831–$9,999,998 | $6,000,392 | 11 similar: 2–15 | No minimum reported similar: $10,000–$54,310 |
| EDGAR ↗ | Relypsa Inc | Director | Sep 14, 2010 | D | $70,129,747 similar: $2,000,000–$19,999,994 | $35,129,747 | 12 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | DFINE INC | Director | Jul 15, 2010 | D | $36,187,884 | $36,165,347 | 25 | $1 |
| EDGAR ↗ | Caduceus Private Investments IV, LP group: Orbimed | Executive Officer, Promoter Member of OrbiMed Advisors | Dec 30, 2009 | D | $550,000,000 similar: $155,000–$5,250,000 | $312,364,000 | 29 similar: 4–27 | No minimum reported similar: $1,000–$100,000 |
| EDGAR ↗ | Enobia Pharma Corp | Director | Aug 28, 2009 | D | $50,000,000 similar: $2,000,000–$19,999,994 | $15,000,000 | 8 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
| EDGAR ↗ | CERAPEDICS INC | Director | Mar 30, 2009 | D | $15,000,000 similar: $2,000,000–$19,999,994 | $15,000,000 | 3 similar: 2–16 | No minimum reported similar: $10,000–$50,000 |
Every row is a Form D or D/A on which the issuer listed this name as a related person. Related-person names are matched on first + last name and the address state on the filing; records that share a name but could not be tied together by a second identifier are listed separately below.
"Similar" = offerings in the same industry claiming the same exemption, filed in the last 5 years (6 industry/exemption sets on this page); ranges are the middle half (25th–75th percentile). Computed by PartnerFacts from SEC EDGAR Form D data as of Oct 23, 2026, 5:45 PM ET. Rows without a range: fewer than 30 comparable filings, or not a Rule 506 offering. No ranking or score.
Not linked to this profile — a second identifier (same issuer, same sponsor group) was not found. Could be the same person or a different one.
People and management entities the issuers listed as related persons on the same Form D filings as Jonathan T. Silverstein. Source: the EDGAR rows in the table above. Showing the 40 with the most shared filings.
None found in sources searched.
Sources searched: SEC Regulation A Data Sets (Forms 1-A, 1-K, 1-Z; 2015 Q2 → 2026 Q3); SEC Crowdfunding Offerings Data Sets (Form C family; 2016 Q2 → 2026 Q3); EDGAR form index for 2026 Q3 → 2026 Q4 · Last checked Oct 23, 2026, 8:41 PM ET.
Export this report as PDF (members · included free during the launch period)
No corrections have been requested for this page.
Free. Logged with status: received → under review → fixed / confirmed with source.
If this is you or your firm, add a sourced explanation next to any fact. Reviewed before publishing.
Members get an email when Jonathan T. Silverstein appears on a new Form D, or when a court case or SEC action is matched to them. See plans →